SPRAVATO

Nasal esketamine spray used to treat adults with:

Treatment-resistant depression (TRD)

Depressive symptoms in adults with major depressive disorder (MDD)

Esketamine is intranasally self-administered, at lower doses, because it is more potent than intravenous and oral ketamine. Esketamine typically has less side effects than ketamine. 

Sedation, Dissociation, Increased Blood Pressure, Nausea.

Patients must be 18 or older.

Your provider may recommend this treatment if you meet the criteria or you can call to schedule a Spravato consultation. 

Anything relaxing. Blankets, pillows, earbuds/headphones, comfortable clothing, etc.

Sandy Springs office. Private treatment room, massage chair, dimmable lights. 

Yes. A driver must always be present at your appointments. No operating heavy machinery the day of treatment.

Treatment is a 2 hour minimum monitoring period. Monitoring can be longer depending on tolerance to the medication.

Weeks 1-4: Twice per week

Weeks 5-8: Once per week

Weeks 9+: Maintenance Phase, dependent on provider’s clinical judgment

      ie: once per week, biweekly, once per month, etc.